Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Expert Reviews Ltd.
Abstract
Methicillin-resistant Staphylococcus aureus has emerged as a major causative pathogen in complicated skin and skin structure infections (cSSSIs). Unfortunately, treatment failure with vancomycin has been increasingly reported. Over the past decade, several alternative antimicrobial agents have been studied and approved for the treatment of cSSSIs. One such agent is the lipoglycopeptide telavancin, which was approved by the US FDA 2009. Given its dual mechanism of action, telavancin is characterized by a highly bactericidal activity and low potential for resistance selection. In addition, in clinical trials, it was efficacious and safe in the treatment of cSSSI. The purpose of this review is to give a background overview of telavancin, highlighting its microbiological, pharmacokinetic and pharmacodynamics characteristics, to summarize the available evidence for its use in the treatment of cSSSIs, and to provide an updated evaluation of its safety profile. © 2015 Informa UK, Ltd.
Description
Keywords
Complicated skin and skin structure infection, Lipoglycopeptide, Methicillin-resistant s. aureus, Telavancin, Vancomycin, Aminoglycosides, Animals, Anti-bacterial agents, Clinical trials as topic, Humans, Methicillin-resistant staphylococcus aureus, Staphylococcal skin infections, Treatment outcome, Nafcillin, Oxacillin, Aminoglycoside, Antiinfective agent, Abnormal urine composition, Antibacterial activity, Area under the curve, Bacterium isolation, Constipation, Drug clearance, Drug distribution, Drug efficacy, Drug elimination, Drug half life, Drug mechanism, Drug penetration, Drug safety, Drug structure, Drug tolerability, Enterococcus faecalis, Headache, Human, Maximum plasma concentration, Methicillin resistant staphylococcus aureus, Methicillin susceptible staphylococcus aureus, Minimum inhibitory concentration, Multicenter study, Nausea, Phase 2 clinical trial (topic), Phase 3 clinical trial (topic), Review, Skin infection, Staphylococcus aureus, Streptococcus pyogenes, Taste disorder, Vomiting, Animal, Clinical trial (topic), Drug effects, Isolation and purification, Procedures